Skip to main content
SpringerLink
Log in

Prädiktive Biomarker als Entscheidungsgrundlage für die onkologische Therapie

Predictive biomarkers as a basis for oncological targeted therapy

  • Fokus
  • Published:
Forum Aims and scope

Zusammenfassung

Die gezielte Unterbrechung molekularer Signalwege („Targeted“-Therapie) ist heute bereits eine wichtige und zukunftsweisende Option in der Behandlung einer Reihe von malignen Tumoren. Voraussetzung ist die genaue Kenntnis der molekularen Zielstrukturen im jeweiligen Tumor, die der Pathologe mit modernen molekularpathologischen Methoden durch den Nachweis prädiktiver Biomarker vor Beginn einer Therapie detektiert und damit erst die Voraussetzung für eine individualisierte zielgerichtete Therapie schafft. Am Beispiel verschiedener Tumoren wird der Stellenwert dieser prädiktiven Biomarker für eine „Targeted“-Therapie dargestellt.

Abstract

The inhibition of molecular signalling pathways (targeted therapy) is already an important and promising option in the therapy of many malignant tumors. A prerequisite is knowledge of the molecular targets in individual tumors which are detected and characterized by pathologists using modern molecular pathological methods and provide the precondition for an individualized targeted therapy. Examples are given demonstrating the crucial role of predictive molecular pathology in determining the molecular targets.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634

    Article  PubMed  CAS  Google Scholar 

  2. Baldus SE, Schaefer KL, Engers R et al (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16:790–799

    Article  PubMed  CAS  Google Scholar 

  3. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697

    Article  PubMed  CAS  Google Scholar 

  4. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643–2648

    Article  PubMed  CAS  Google Scholar 

  5. Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626–632

    Article  PubMed  CAS  Google Scholar 

  6. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516

    Article  PubMed  CAS  Google Scholar 

  7. Di Fiore F, Blanchard F, Charbonnier F et al (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96:1166–1169

    Article  Google Scholar 

  8. Freeman DJ, Juan T, Reiner M et al (2008) Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7:184–190

    Article  PubMed  CAS  Google Scholar 

  9. Kwak EL, Bang YL, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703

    Article  PubMed  CAS  Google Scholar 

  10. Liegl-Atzwanger B, Fletcher JA, Fletcher CD (2010) Gastrointestinal stromal tumors. Virchows Arch 456:111–127

    Article  PubMed  Google Scholar 

  11. Long GV, Menzies AM, Nagrial AM et al (2011) Prognostic and cliniopathological associations of oncogenic BRAF in mestastatic melanoma. J Clin Oncol 29:1239–1246

    Article  PubMed  Google Scholar 

  12. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957

    Article  PubMed  CAS  Google Scholar 

  13. Murray S, Dahabreh IJ,Linardou H et al (2008) Somatic mutationsof the tyrosine kinase domainof epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer:An analytical database. J Thorac Oncol 3:832–839

    Article  PubMed  Google Scholar 

  14. Penzel R, Sers C, Chen Y et al (2010) EGFR mutation detection in NSCLC-assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch 458:95–98

    Article  PubMed  Google Scholar 

  15. Querings S, Altmuller J, Ansen S et al (2011) Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 6:e19601

    Article  PubMed  CAS  Google Scholar 

  16. Reinersman JM, Johnson ML, Riely GJ et al (2011) Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 6:28–31

    Article  PubMed  Google Scholar 

  17. Rubinstein JC, Sznol M, Pavlick AC et al (2010) Incidence of the V600 K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 8:67

    Article  PubMed  Google Scholar 

  18. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–181

    Article  PubMed  CAS  Google Scholar 

  19. Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566

    Article  PubMed  CAS  Google Scholar 

  20. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134

    Article  PubMed  CAS  Google Scholar 

  21. Yang CH, Yu CJ, Shih JY et al (2008) Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26:2745–2753

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung hin: Advisory Board Amgen.

Author information

Authors and Affiliations

  1. Institut für Pathologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland

    H.E. Gabbert

  2. Institut für Pathologie, Ludwig-Maximilians-Universität München, München, Deutschland

    T. Kirchner

  3. Vorsitzender der Arbeitsgemeinschaft Onkologische Pathologie ( AOP), Düsseldorf, Deutschland

    H.E. Gabbert

Authors
  1. H.E. Gabbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Kirchner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gabbert, H., Kirchner, T. Prädiktive Biomarker als Entscheidungsgrundlage für die onkologische Therapie. Forum 27, 27–32 (2012). https://doi.org/10.1007/s12312-011-0723-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12312-011-0723-2

Schlüsselwörter

Keywords

Search

Navigation